These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29514049)

  • 1. Comparison of Drug-Eluting Stent with Bare-Metal Stent Implantation in Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis.
    Ding Y; Zhou M; Wang Y; Cai L; Shi Z
    Ann Vasc Surg; 2018 Jul; 50():96-105. PubMed ID: 29514049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
    Antoniou GA; Georgakarakos EI; Antoniou SA; Georgiadis GS
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):282-5. PubMed ID: 24729201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angioplasty or bare metal stent versus drug-eluting endovascular treatment in femoropopliteal artery disease: a systematic review and meta-analysis.
    Varetto G; Gibello L; Boero M; Frola E; Peretti T; Spalla F; Verzini F; Rispoli P
    J Cardiovasc Surg (Torino); 2019 Oct; 60(5):546-556. PubMed ID: 31527577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Endovascular Treatment Modalities for De Novo Femoropopliteal Lesions: A Network Meta-analysis of Randomized Controlled Trials.
    Zhou Y; Zhang Z; Lin S; Xiao J; Ai W; Wang J; Li Y; Li Q
    J Endovasc Ther; 2020 Feb; 27(1):42-59. PubMed ID: 31948375
    [No Abstract]   [Full Text] [Related]  

  • 5. A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease.
    Ansel GM; Jaff MR; Popma JJ; Battisti AJ; Lottes AE; Harnish P; Dake MD
    J Endovasc Ther; 2017 Aug; 24(4):499-503. PubMed ID: 28485182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Plain Balloon Angioplasty, Bare Metal Stents, Drug-Coated Balloons, and Drug-Eluting Stents for the Treatment of Infrapopliteal Artery Disease: Systematic Review and Bayesian Network Meta-analysis of Randomized Controlled Trials.
    Katsanos K; Kitrou P; Spiliopoulos S; Diamantopoulos A; Karnabatidis D
    J Endovasc Ther; 2016 Dec; 23(6):851-863. PubMed ID: 27708143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization.
    Jeon-Slaughter H; Khalili H; Tsai S; Armstrong EJ; Shammas NW; Jawaid O; Lu H; Addo T; Gigliotti O; Abu-Fadel M; Banerjee S
    J Invasive Cardiol; 2018 Oct; 30(10):373-379. PubMed ID: 30279293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
    Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
    JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
    Gouëffic Y; Torsello G; Zeller T; Esposito G; Vermassen F; Hausegger KA; Tepe G; Thieme M; Gschwandtner M; Kahlberg A; Schindewolf M; Sapoval M; Diaz-Cartelle J; Stavroulakis K;
    Circulation; 2022 Nov; 146(21):1564-1576. PubMed ID: 36254728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mortality with paclitaxel-eluting stents is driven by lesion length.
    Mathlouthi A; Yei KS; Naazie I; Bertges DJ; Malas MB
    J Vasc Surg; 2021 Feb; 73(2):548-553.e2. PubMed ID: 32615286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bare metal vs. drug-eluting stents for extracranial vertebral artery disease: a meta-analysis of nonrandomized comparative studies.
    Langwieser N; Buyer D; Schuster T; Haller B; Laugwitz KL; Ibrahim T
    J Endovasc Ther; 2014 Oct; 21(5):683-92. PubMed ID: 25290797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propensity Score Analysis Comparing Clinical Outcomes of Drug-Eluting vs Bare Nitinol Stents in Femoropopliteal Lesions.
    Soga Y; Takahara M; Iida O; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Ando K
    J Endovasc Ther; 2016 Feb; 23(1):33-9. PubMed ID: 26763256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
    Gouëffic Y; Kaladji A; Guyomarch B; Montagne C; Fairier D; Gestin S; Riche VP; Vent PA; Chaillou P; Costargent A; Patra P
    Trials; 2014 Oct; 15():423. PubMed ID: 25359394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-Analysis Comparing Endovascular Treatment Modalities for Femoropopliteal Peripheral Artery Disease.
    Khan MS; Zou F; Khan AR; Moustafa A; Schmid CH; Baig M; Hyder ON; Aronow HD
    Am J Cardiol; 2020 Aug; 128():181-188. PubMed ID: 32650917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.
    Vent PA; Kaladji A; Davaine JM; Guyomarch B; Chaillou P; Costargent A; Quillard T; Gouëffic Y
    Ann Vasc Surg; 2017 Aug; 43():166-175. PubMed ID: 28300676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of drug-eluting stents for the treatment of femoropopliteal disease provides significant cost-to-system savings in a single-state outpatient simulation.
    Sridharan ND; Liang N; Robinson D; Avgerinos E; Tzeng E; Makaroun MS; Chaer RA; Eslami MH
    J Vasc Surg; 2018 Nov; 68(5):1465-1472. PubMed ID: 29779962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.